8-K Announcements
6Material company update
Mar 26, 2026·SEC
Material company update
Mar 16, 2026·SEC
Material company update
Jan 16, 2026·SEC
Agenus Inc.(AGEN)Earnings, Financials & Key Ratios
AGEN•NASDAQ
$3.89
$137M mkt cap·Price updated May 6, 2026
AboutAgenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, the company develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS, as well as in clinical stage to treat hematological malignancies and multiple myeloma/B cells; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. operates under ASV, Agenus, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.Show more
- Revenue$114M+10.4%
- EBITDA-$11M+90.1%
- Net Income$115K+100.1%
- EPS (Diluted)-0.00+100.0%
- Gross Margin90.35%+277.9%
- EBITDA Margin-9.24%+91.1%
- Operating Margin-18%+84.5%
- Net Margin0.1%+100.0%
- Interest Coverage-0.37+63.9%
AGEN Key Insights
Agenus Inc. (AGEN) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Negative free cash flow
- ✗Shares diluted 38.5% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
AGEN Price & Volume
Agenus Inc. (AGEN) stock price & volume — 10-year historical chart
Loading chart...
AGEN Growth Metrics
Agenus Inc. (AGEN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years16.49%
5 Years5.31%
3 Years5.22%
TTM10.37%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM100.05%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM96.37%
Return on Capital
10 Years-135.82%
5 Years-137.56%
3 Years-248.03%
Last Year-
AGEN Recent Earnings
Agenus Inc. (AGEN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 6/12 qtrs (50%)
Q2 2026Latest
Mar 16, 2026EPS
$0.56
Est $1.27
+144.1%
Revenue
$34M
Est $28M
+21.7%
Q4 2025
Nov 10, 2025EPS
$1.94
Est $2.63
-26.2%
Revenue
$30M
Est $28M
+7.6%
Q3 2025
Aug 11, 2025EPS
$1.00
Est $0.78
-28.2%
Revenue
$26M
Est $25M
+2.8%
Q2 2025
May 12, 2025EPS
$1.03
Est $1.61
+36.0%
Revenue
$24M
Est $22M
+8.9%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 16, 2026 | $0.56vs $1.27+144.1% | $34Mvs $28M+21.7% |
| Q4 2025 | Nov 10, 2025 | $1.94vs $2.63-26.2% | $30Mvs $28M+7.6% |
| Q3 2025 | Aug 11, 2025 | $1.00vs $0.78-28.2% | $26Mvs $25M+2.8% |
| Q2 2025 | May 12, 2025 | $1.03vs $1.61+36.0% | $24Mvs $22M+8.9% |
Based on last 12 quarters of dataView full earnings history →
AGEN Peer Comparison
Agenus Inc. (AGEN) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NKTR | 1.67B | 85.09 | -8.75 | -43.89% | -192.87% | -356.81% | 0.95 | |
 INCY | 19.95B | 99.85 | 15.58 | 21.22% | 26.71% | 29.31% | 0.01 | |
 EXEL | 12.37B | 48.70 | 17.52 | 6.98% | 35.08% | 40.21% | 0.08 | |
 RCUS | 2.62B | 26.00 | -7.90 | -4.26% | -156.36% | -68.97% | 0.16 | |
 MGNX | 190.59M | 3.01 | -2.55 | 0.78% | -49.91% | -120.2% | 0.66 | |
 ALKS | 5.89B | 35.32 | 24.70 | -5.25% | 9.78% | 8.82% | 0.04 | |
 FATE | 264.17M | 2.29 | -1.99 | -51.24% | -20.51% | -65.79% | 0.38 | |
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 |
Compare AGEN vs Peers
Agenus Inc. (AGEN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
AGEN Income Statement
Agenus Inc. (AGEN) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 42.88M | 36.78M | 150.05M | 88.17M | 295.67M | 98.02M | 156.31M | 103.46M | 114.2M |
| Revenue Growth % | 89.95% | -14.21% | 307.92% | -41.24% | 235.34% | -66.85% | 59.47% | -33.81% | 10.37% |
| Cost of Goods Sold | 116.13M | 124.6M | 168.34M | 144.97M | 182.08M | 197.26M | 237.68M | 156.01M | 11.02M |
| COGS % of Revenue | 270.83% | 338.74% | 112.19% | 164.42% | 61.58% | 201.24% | 152.05% | 150.79% | 9.65% |
| Gross Profit | -73.25M▲ 0% | -87.82M▼ 19.9% | -18.29M▲ 79.2% | -56.8M▼ 210.5% | 113.59M▲ 300.0% | -99.23M▼ 187.4% | -81.37M▲ 18.0% | -52.55M▲ 35.4% | 103.17M▲ 296.3% |
| Gross Margin % | -170.83% | -238.74% | -12.19% | -64.42% | 38.42% | -101.24% | -52.05% | -50.79% | 90.35% |
| Gross Profit Growth % | -1.17% | -19.89% | 79.17% | -210.51% | 299.99% | -187.36% | 18.01% | 35.41% | 296.33% |
| Operating Expenses | 33.74M | 37.34M | 51.85M | 60.44M | 87.84M | 80.19M | 78.18M | 67.92M | 123.73M |
| OpEx % of Revenue | 78.69% | 101.51% | 34.55% | 68.55% | 29.71% | 81.81% | 50.02% | 65.65% | 108.35% |
| Selling, General & Admin | 33.74M | 37.34M | 46.04M | 59.22M | 76.36M | 81.01M | 78.74M | 71.88M | 44.39M |
| SG&A % of Revenue | 78.69% | 101.51% | 30.68% | 67.16% | 25.83% | 82.64% | 50.37% | 69.47% | 38.87% |
| Research & Development | 116.13M | 124.6M | 168.34M | 142.62M | 178.61M | 0 | 234.57M | 155.53M | 79.34M |
| R&D % of Revenue | 270.83% | 338.74% | 112.19% | 161.75% | 60.41% | - | 150.06% | 150.32% | 69.48% |
| Other Operating Expenses | -16.89M | -2.18M | -162.53M | -141.4M | -167.13M | -815K | -235.13M | -159.48M | 0 |
| Operating Income | -103.8M▲ 0% | -123.82M▼ 19.3% | -70.14M▲ 43.4% | -117.23M▼ 67.2% | 25.75M▲ 122.0% | -179.43M▼ 796.9% | -159.55M▲ 11.1% | -120.47M▲ 24.5% | -20.56M▲ 82.9% |
| Operating Margin % | -242.09% | -336.62% | -46.74% | -132.96% | 8.71% | -183.04% | -102.07% | -116.44% | -18% |
| Operating Income Growth % | 3.42% | -19.29% | 43.36% | -67.15% | 121.96% | -796.89% | 11.08% | 24.49% | 82.94% |
| EBITDA | -97.79M | -117.53M | -63.48M | -110.06M | 32.53M | -172.48M | -145.96M | -107.13M | -10.56M |
| EBITDA Margin % | -228.08% | -319.53% | -42.3% | -124.82% | 11% | -175.96% | -93.38% | -103.55% | -9.24% |
| EBITDA Growth % | 4.62% | -20.18% | 45.99% | -73.38% | 129.56% | -630.14% | 15.38% | 26.6% | 90.15% |
| D&A (Non-Cash Add-back) | 6.01M | 6.29M | 6.66M | 7.18M | 6.79M | 6.95M | 13.59M | 13.34M | 10M |
| EBIT | -101.82M | -136.77M | -70.11M | -121.81M | 36.99M | -168.79M | -159.51M | -114.64M | -20.56M |
| Net Interest Income | -18.87M | -25.27M | -41.45M | -61.08M | -65.72M | -61.86M | -97.92M | -117.63M | -55.27M |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 345K |
| Interest Expense | 18.87M | 25.27M | 41.45M | 61.08M | 65.72M | 61.86M | 97.92M | 117.63M | 55.62M |
| Other Income/Expense | -16.89M | -38.22M | -41.42M | -65.66M | -54.47M | -51.23M | -97.89M | -111.8M | 17.47M |
| Pretax Income | -120.69M▲ 0% | -162.04M▼ 34.3% | -111.56M▲ 31.2% | -182.89M▼ 63.9% | -28.72M▲ 84.3% | -230.66M▼ 703.0% | -257.44M▼ 11.6% | -232.27M▲ 9.8% | -3.08M▲ 98.7% |
| Pretax Margin % | -281.48% | -440.53% | -74.35% | -207.43% | -9.71% | -235.31% | -164.69% | -224.5% | -2.7% |
| Income Tax | 0 | -12.95M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 7.99% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -120.69M▲ 0% | -159.69M▼ 32.3% | -107.66M▲ 32.6% | -180.91M▼ 68.0% | -23.93M▲ 86.8% | -220.07M▼ 819.8% | -245.76M▼ 11.7% | -227.21M▲ 7.5% | 115K▲ 100.1% |
| Net Margin % | -281.48% | -434.14% | -71.75% | -205.19% | -8.09% | -224.51% | -157.22% | -219.61% | 0.1% |
| Net Income Growth % | 4.96% | -32.31% | 32.58% | -68.05% | 86.77% | -819.81% | -11.67% | 7.55% | 100.05% |
| Net Income (Continuing) | -120.69M | -162.04M | -111.56M | -182.89M | -28.72M | -230.66M | -257.44M | -232.27M | -3.08M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | -2.08M | -5.98M | -7.83M | 13.47M | 6.38M | 11.95M | 19.96M | -6.75M |
| EPS (Diluted) | -24.53▲ 0% | -28.83▼ 17.5% | -22.10▲ 23.3% | -21.00▲ 5.0% | -2.11▲ 90.0% | -15.64▼ 641.2% | -13.75▲ 12.1% | -10.59▲ 23.0% | -0.00▲ 100.0% |
| EPS Growth % | 15.91% | -17.53% | 23.34% | 4.98% | 89.95% | -641.23% | 12.08% | 22.98% | 99.97% |
| EPS (Basic) | -24.53 | -28.83 | -22.10 | -21.00 | -2.11 | -15.64 | -13.75 | -10.59 | -0.00 |
| Diluted Shares Outstanding | 4.92M | 5.54M | 6.75M | 8.63M | 11.45M | 14.09M | 17.89M | 21.47M | 29.73M |
| Basic Shares Outstanding | 4.92M | 5.54M | 6.75M | 8.63M | 11.45M | 14.09M | 17.89M | 21.47M | 29.73M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
AGEN Balance Sheet
Agenus Inc. (AGEN) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 73.55M | 74.81M | 86.54M | 113.78M | 331.97M | 213.12M | 112.42M | 45.57M | 133.44M |
| Cash & Short-Term Investments | 60.19M | 53.05M | 61.81M | 99.87M | 306.92M | 193.36M | 76.11M | 40.44M | 3M |
| Cash Only | 60.19M | 53.05M | 61.81M | 99.87M | 291.93M | 178.67M | 76.11M | 40.44M | 3M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 14.99M | 14.68M | 0 | 0 | 0 |
| Accounts Receivable | 1.13M | 938.14K | 16.29M | 1.16M | 1.52M | 2.74M | 25.84M | 407K | 1.83M |
| Days Sales Outstanding | 9.66 | 9.31 | 39.63 | 4.79 | 1.87 | 10.21 | 60.33 | 1.44 | 5.85 |
| Inventory | 79.49K | 55.49K | 7.42M | 0 | 20.36M | 13.83M | 0 | 0 | 0 |
| Days Inventory Outstanding | 0.25 | 0.16 | 16.09 | - | 40.82 | 25.59 | - | - | - |
| Other Current Assets | 1.08M | 1.5M | -6.41M | 2.01M | -17.19M | -10.63M | 2.37M | 2.42M | 128.61M |
| Total Non-Current Assets | 82.2M | 61.59M | 68.8M | 100.73M | 133.98M | 200.43M | 201.5M | 180.7M | 93.36M |
| Property, Plant & Equipment | 26.18M | 25.12M | 33.69M | 60.27M | 91.08M | 164.29M | 163.03M | 147.4M | 24.25M |
| Fixed Asset Turnover | 1.64x | 1.46x | 4.45x | 1.46x | 3.25x | 0.60x | 0.96x | 0.70x | 4.71x |
| Goodwill | 23.05M | 22.92M | 23.19M | 25.45M | 24.88M | 25.47M | 24.72M | 24.09M | 24.09M |
| Intangible Assets | 31.76M | 12.34M | 10.5M | 10.89M | 8.49M | 6.23M | 4.41M | 3.38M | 3.04M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 3.22M | 0 | 42.73M |
| Other Non-Current Assets | 1.21M | 1.21M | 1.42M | 4.12M | 12.21M | 7.12M | 6.11M | 5.83M | -742K |
| Total Assets | 138.4M▲ 0% | 136.4M▼ 1.4% | 155.34M▲ 13.9% | 214.51M▲ 38.1% | 465.96M▲ 117.2% | 413.56M▼ 11.2% | 313.91M▼ 24.1% | 226.27M▼ 27.9% | 226.8M▲ 0.2% |
| Asset Turnover | 0.31x | 0.27x | 0.97x | 0.41x | 0.63x | 0.24x | 0.50x | 0.46x | 0.50x |
| Asset Growth % | -11.84% | -1.45% | 13.88% | 38.1% | 117.22% | -11.25% | -24.09% | -27.92% | 0.23% |
| Total Current Liabilities | 56.44M | 68.06M | 122.21M | 129.88M | 156.94M | 188.95M | 255.9M | 221.4M | 323.49M |
| Accounts Payable | 8.09M | 13.62M | 13.56M | 17.02M | 30.49M | 40.94M | 61.45M | 61.47M | 82.99M |
| Days Payables Outstanding | 25.42 | 39.91 | 29.41 | 42.84 | 61.11 | 75.75 | 94.36 | 143.81 | 2.75K |
| Short-Term Debt | 20.64M | 146K | 646K | 833K | 728K | 575K | 146K | 2.7M | 155.11M |
| Deferred Revenue (Current) | 4.48M | 1.81M | 29.17M | 17.19M | 12.43M | 12.27M | 18K | 31K | 1.14M |
| Other Current Liabilities | 3.22M | 43.71M | 48.15M | 69.88M | 75.66M | 101.49M | 141.21M | 121.85M | 84.25M |
| Current Ratio | 1.30x | 1.10x | 0.71x | 0.88x | 2.12x | 1.13x | 0.44x | 0.21x | 0.41x |
| Quick Ratio | 1.30x | 1.10x | 0.65x | 0.88x | 1.99x | 1.05x | 0.44x | 0.21x | 0.41x |
| Cash Conversion Cycle | -15.51 | -30.44 | 26.31 | - | -18.42 | -39.96 | - | - | - |
| Total Non-Current Liabilities | 157.78M | 242.88M | 264.46M | 296.13M | 261.11M | 279.51M | 206.4M | 311.29M | 10.11M |
| Long-Term Debt | 142.39M | 13.21B | 13.38M | 18.88M | 12.82M | 12.58M | 12.77M | 30.47M | 10.11M |
| Capital Lease Obligations | 0 | -13.2B | 8.02M | 34.06M | 42.11M | 63.33M | 67.23M | 54.55M | 10.13M |
| Deferred Tax Liabilities | 0 | 182.82M | 26.92M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 7.65M | -13.15B | 188.44M | 214.9M | 194.97M | 202.45M | 125.26M | 225.13M | 242K |
| Total Liabilities | 214.22M | 310.95M | 386.67M | 426.01M | 418.05M | 468.46M | 462.3M | 532.7M | 333.6M |
| Total Debt | 163.02M | 13.36M | 23.39M | 55.73M | 58.29M | 78.43M | 93.19M | 94.87M | 10.11M |
| Net Debt | 102.84M | -39.7M | -38.41M | -44.14M | -233.64M | -100.25M | 17.08M | 54.43M | 7.11M |
| Debt / Equity | - | - | - | - | 1.22x | - | - | - | - |
| Debt / EBITDA | - | - | - | - | 1.79x | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | -7.18x | - | - | - | - |
| Interest Coverage | -5.50x | -4.90x | -1.69x | -1.92x | 0.39x | -2.90x | -1.63x | -1.02x | -0.37x |
| Total Equity | -75.82M▲ 0% | -174.55M▼ 130.2% | -231.34M▼ 32.5% | -211.5M▲ 8.6% | 47.91M▲ 122.7% | -54.9M▼ 214.6% | -148.38M▼ 170.3% | -306.42M▼ 106.5% | -113.55M▲ 62.9% |
| Equity Growth % | -93.77% | -130.22% | -32.54% | 8.58% | 122.65% | -214.6% | -170.27% | -106.51% | 62.94% |
| Book Value per Share | -15.41 | -31.51 | -34.28 | -24.52 | 4.19 | -3.90 | -8.29 | -14.27 | -3.82 |
| Total Shareholders' Equity | -75.82M | -172.47M | -225.36M | -203.67M | 34.44M | -61.28M | -160.33M | -326.38M | -271.11M |
| Common Stock | 1.02M | 1.2M | 1.38M | 1.96M | 2.57M | 3.06M | 3.94M | 236K | 353K |
| Retained Earnings | -1.03B | -1.18B | -1.28B | -1.47B | -1.49B | -1.71B | -1.96B | -2.18B | -2.18B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -2.17M | -1.54M | -1.32M | 2.77M | 1.49M | 915K | -955K | -1.4M | -439K |
| Minority Interest | 0 | -2.08M | -5.98M | -7.83M | 13.47M | 6.38M | 11.95M | 19.96M | -6.75M |
AGEN Cash Flow Statement
Agenus Inc. (AGEN) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -94.23M | -131.09M | -18.68M | -139.1M | 10.14M | -175.37M | -224.2M | -158.31M | -158.31M |
| Operating CF Margin % | -219.76% | -356.39% | -12.45% | -157.76% | 3.43% | -178.91% | -143.43% | -153.02% | -138.63% |
| Operating CF Growth % | -17.84% | -39.13% | 85.75% | -644.55% | 107.29% | -1828.66% | -27.84% | 29.39% | 0% |
| Net Income | -120.69M | -162.04M | -111.56M | -182.89M | -28.72M | -230.66M | -257.44M | -232.27M | -232.27M |
| Depreciation & Amortization | 6.01M | 6.29M | 6.66M | 7.18M | 6.79M | 6.95M | 13.59M | 13.34M | 13.34M |
| Stock-Based Compensation | 12.43M | 7.63M | 9.89M | 10.42M | 19.58M | 18.34M | 22.87M | 17.39M | 17.39M |
| Deferred Taxes | 23.56K | 10.91M | 58K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 14.49M | 5.95M | 17.58M | 17.25M | 22.25M | 5.92M | -13.98M | 10.62M | 15.89M |
| Working Capital Changes | -6.48M | 170.05K | 58.68M | 8.95M | -9.74M | 24.08M | 10.76M | 32.6M | 27.33M |
| Change in Receivables | 10.22M | 196.35K | -15.36M | 16.19M | -394K | 122K | -23.46M | 25.34M | -1.73M |
| Change in Inventory | 8.71K | 24K | 55K | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 1.65M | 5.37M | -234K | 2.77M | 10.82M | 6.49M | 21.37M | 2.01M | 23.5M |
| Cash from Investing | 2.06M | -3.59M | -4.66M | -4.44M | -43.15M | -33.61M | 3.4M | 27K | 27K |
| Capital Expenditures | -3.12M | -3.6M | -4.66M | -3.47M | -33.81M | -53.06M | -9.95M | -576K | -576K |
| CapEx % of Revenue | 7.28% | 9.78% | 3.1% | 3.93% | 11.44% | 54.13% | 6.37% | 0.56% | 0.5% |
| Acquisitions | 120K | 6.19K | 0 | -975K | 0 | -2.92M | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 120K | 6.19K | 0 | 0 | 5.66M | 22M | 3.36M | 24K | 24K |
| Cash from Financing | 80.54M | 128.28M | 31.32M | 183.85M | 225.26M | 95.83M | 119.87M | 122.84M | 122.84M |
| Debt Issued (Net) | 14.52M | -162.13M | -320K | 2.96M | -1.32M | -490K | -8.93M | 9.52M | 2.35M |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -527K | 0 | 0 | 0 | -1.65M | -3.79M | -5.17M | 0 | -87K |
| Other Financing | 775 | 204.39M | 1.64M | 4.47M | 7.59M | 898K | 807K | 74.5M | 84.27M |
| Net Change in Cash | -11.26M▲ 0% | -7.13M▲ 36.7% | 8.75M▲ 222.7% | 40.7M▲ 364.9% | 192.09M▲ 372.0% | -113.26M▼ 159.0% | -101.56M▲ 10.3% | -35.71M▲ 64.8% | -35.71M▲ 0.0% |
| Free Cash Flow | -97.35M▲ 0% | -134.69M▼ 38.4% | -23.34M▲ 82.7% | -142.56M▼ 510.8% | -23.67M▲ 83.4% | -228.44M▼ 865.1% | -234.16M▼ 2.5% | -158.89M▲ 32.1% | -158.89M▲ 0.0% |
| FCF Margin % | -227.03% | -366.17% | -15.55% | -161.69% | -8.01% | -233.04% | -149.8% | -153.57% | -139.14% |
| FCF Growth % | -5.26% | -38.36% | 82.67% | -510.83% | 83.4% | -865.12% | -2.5% | 32.14% | 0% |
| FCF per Share | -19.78 | -24.32 | -3.46 | -16.53 | -2.07 | -16.22 | -13.09 | -7.40 | -5.34 |
| FCF Conversion (FCF/Net Income) | 0.78x | 0.82x | 0.17x | 0.77x | -0.42x | 0.80x | 0.91x | 0.70x | -1376.65x |
| Interest Paid | 0 | 0 | 0 | 1.18M | 1.15M | 1.14M | 3.17M | 2.28M | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
AGEN Key Ratios
Agenus Inc. (AGEN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -803.72% | - | - | - | - | -49.94% | - | - | - | - |
| Return on Invested Capital (ROIC) | -562.55% | -369.42% | - | - | - | - | - | - | - | - |
| Gross Margin | -320.73% | -170.83% | -238.74% | -12.19% | -64.42% | 38.42% | -101.24% | -52.05% | -50.79% | 90.35% |
| Net Margin | -562.6% | -281.48% | -434.14% | -71.75% | -205.19% | -8.09% | -224.51% | -157.22% | -219.61% | 0.1% |
| Debt / Equity | - | - | - | - | - | 1.22x | - | - | - | - |
| Interest Coverage | -6.21x | -5.50x | -4.90x | -1.69x | -1.92x | 0.39x | -2.90x | -1.63x | -1.02x | -0.37x |
| FCF Conversion | 0.63x | 0.78x | 0.82x | 0.17x | 0.77x | -0.42x | 0.80x | 0.91x | 0.70x | -1376.65x |
| Revenue Growth | -9.04% | 89.95% | -14.21% | 307.92% | -41.24% | 235.34% | -66.85% | 59.47% | -33.81% | 10.37% |
AGEN SEC Filings & Documents
Agenus Inc. (AGEN) SEC filings — annual & quarterly reports (10-K, 10-Q)
AGEN Frequently Asked Questions
Agenus Inc. (AGEN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Agenus Inc. (AGEN) reported $114.2M in revenue for fiscal year 2025. This represents a 114096% increase from $0.1M in 1999.
Agenus Inc. (AGEN) grew revenue by 10.4% over the past year. This is steady growth.
Yes, Agenus Inc. (AGEN) is profitable, generating $0.1M in net income for fiscal year 2025 (0.1% net margin).
Dividend & Returns
Agenus Inc. (AGEN) had negative free cash flow of $158.9M in fiscal year 2025, likely due to heavy capital investments.
Explore More AGEN
Agenus Inc. (AGEN) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates